SINGAPORE and IRVINE, Calif., Oct. 27 /PRNewswire/ -- PrimeGen Biotech, LLC, a 3 year old privately-held stem cell engineering firm, announced today that it will present results of its research on the therapeutic reprogramming of murine germ-line stem cells at the Keystone Symposium on Stem Cells, Senescence and Cancer, currently being held in Singapore. The poster presentation will occur on Friday, October 28 from 3:30 to 5:30 PM at the conference.
The company’s data demonstrate that post-natal murine germ-line stem cells, which normally differentiate only into sperm and eggs, can be reprogrammed to be pluripotent. These reprogrammed germ-line stem cells, which the company has termed PrimeCell(TM), express embryonic stem cell (ESC)-specific markers and were successfully directed to differentiate into multiple tissue types, including cardiac muscle and neural cell types. The data also demonstrate that therapeutically reprogrammed germ-line stem cells injected into mouse blastocysts give rise to all three germ layers in the murine embryo, substantiating the finding that the cells are pluripotent.
Unlike existing embryonic stem cell lines or adult stem cell lines from any other known source, germ-line stem cells possess a uniquely conserved genome. These cells have been evolutionarily conserved to maintain the highest level of genetic integrity, which enables successful propagation of species.
“Our work with murine spermatogonial stem cells demonstrates the potential to apply our therapeutic reprogramming approach to human-derived germ-line cells for the development of regenerative therapies,” said Francisco Silva, Executive Vice President of R&D at PrimeGen. “Because of PrimeCell’s unique genetic integrity, conditioned pluripotentiality and the fact that it is derived from a post-natal source, we believe it will be the most therapeutically valuable stem cell available to treat a wide range of degenerative disorders.”
About Keystone Symposia
Keystone Symposia, a non-profit organization, has a 35-year history of organizing high quality scientific conferences to connect the scientific community and accelerate discoveries that benefit society.
About PrimeGen Biotech, LLC
Founded in 2002, PrimeGen Biotech, LLC is a privately-held stem cell engineering firm dedicated to optimizing the therapeutic potential of adult stem cells. The company’s premier platform, PrimeCell(TM), is based on the therapeutic reprogramming of germ-line stem cells to yield a pristine, pluripotent adult stem cell. For more information, visit www.primegenbiotech.com.
CONTACT: Virginia Amann or Jennifer MacArthur Atkins + Associates for PrimeGen Biotech 608-274-6046 or 858-527-3497 vamann@irpr.comjmacarthur@irpr.com
PrimeGen Biotech, LLC
CONTACT: Virginia Amann, +1-608-274-6046, vamann@irpr.com, or JenniferMacArthur, +1-858-527-3497, jmacarthur@irpr.com, both of Atkins +Associates, for PrimeGen Biotech, LLC
Web site: http://www.primegenbiotech.com/
